1. Limited disease progression in endocrine surgery patients with treatment delays due to COVID-19
- Author
-
Reagan A. Collins, Catherine DiGennaro, Toni Beninato, Rajshri M. Gartland, Natalia Chaves, Jordan M. Broekhuis, Lekha Reddy, Jenna Lee, Angelina Deimiller, Maeve M. Alterio, Michael J. Campbell, Yeon Joo Lee, Tyler K. Khilnani, Latoya A. Stewart, Mollie A. O’Brien, Miguel Valdivia y Alvarado, Feibi Zheng, David McAneny, Rachel Liou, Catherine McManus, Sophie Y. Dream, Tracy S. Wang, Tina W. Yen, Amal Alhefdhi, Brendan M. Finnerty, Thomas J. Fahey, Claire E. Graves, Amanda M. Laird, Matthew A. Nehs, Frederick Thurston Drake, James A. Lee, Christopher R. McHenry, Benjamin C. James, Janice L. Pasieka, Jennifer H. Kuo, and Carrie Cunningham Lubitz
- Subjects
Male ,SARS-CoV-2 ,Clinical Sciences ,COVID-19 ,Middle Aged ,Endocrine System Diseases ,Time-to-Treatment ,Clinical Research ,Disease Progression ,Humans ,Female ,Surgery ,Patient Safety ,Digestive Diseases ,Pandemics - Abstract
BackgroundThe COVID-19 pandemic profoundly impacted the delivery of care and timing of elective surgical procedures. Most endocrine-related operations were considered elective and safe to postpone, providing a unique opportunity to assess clinical outcomes under protracted treatment plans.MethodsAmerican Association of Endocrine Surgeon members were surveyed for participation. A Research Electronic Data Capture survey was developed and distributed to 27 institutions to assess the impact of COVID-19-related delays. The information collected included patient demographics, primary diagnosis, resumption of care, and assessment of disease progression by the surgeon.ResultsTwelve out of 27 institutions completed the survey (44.4%). Of 850 patients, 74.8% (636) were female; median age was 56 (interquartile range, 44-66) years. Forty percent (34) of patients had not been seen since their original surgical appointment was delayed; 86.2% (733) of patients had a delay in care with women more likely to have a delay (87.6% vs 82.2% of men, χ2= 3.84, P= .05). Median duration of delay was 70 (interquartile range, 42-118) days. Among patients with a delay in care, primary disease site included thyroid (54.2%), parathyroid (37.2%), adrenal (6.5%), and pancreatic/gastrointestinal neuroendocrine tumors (1.3%). In addition, 4.0% (26) of patients experienced disease progression and 4.1% (24) had a change from the initial operative plan. The duration of delay was not associated with disease progression (P= .96) or a change in operative plan (P= .66).ConclusionAlthough some patients experienced disease progression during COVID-19 delays to endocrine disease-related care, most patients with follow-up did not. Our analysis indicated that temporary delay may be an acceptable course of action in extreme circumstances for most endocrine-related surgical disease.
- Published
- 2023